Idiopathic pulmonary fibrosis (IPF) is an orphan disease affecting approximately 50,000 people in the United States. It is characterized by the thickening and stiffening of tissues in the lungs. Although the prognosis for patients diagnosed with IPF is poor (survival of three to five years after diagnosis in most cases), various therapies can relieve symptoms, prevent further lung scarring, and improve patients’ quality of life. Different drug classes are used to target the respective physiological mechanisms. For example, tyrosine kinase inhibitors (e.g., nintedanib [Boehringer Ingelheim’s Ofev]) block the action of enzymes that cause fibrosis, while antifibrotic agents such as pirfenidone (Roche/Genentech’s Esbriet) reduce lung fibrosis by downregulating the production of growth factors. This analysis of patient-level claims data provides insight into the dynamics of the IPF treatment landscape.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States.
Key companies: Boehringer Ingelheim, Roche / Genentech.
Key drugs: Azathioprine, benralizumab, nintedanib, pirfenidone, sildenafil.
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and optional quarterly data refreshes.